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Abstract
Background: Acute brainstem syndrome (ABS) may herald multiple sclerosis (MS), neuromyelitis optica (NMO), or
occur as an isolated syndrome. The aquaporin 4 (AQP4)-specific serum autoantibody, NMO-IgG, is a biomarker for
NMO. However, the role of anti-AQP4 antibody in the conversion of ABS to NMO is unclear.
Methods: Thirty-one patients with first-event ABS were divided into two groups according to the presence of
anti-AQP4 antibodies, their clinical features and outcomes were retrospectively analyzed.
Results: Fourteen of 31 patients (45.16 %) were seropositive for NMO-IgG. The 71.43 % of anti-AQP4 (+) ABS
patients converted to NMO, while only 11.76 % of anti-AQP4 (-) ABS patients progressed to NMO. Anti-AQP4 (+)
ABS patients demonstrated a higher IgG index (0.68 ± 0.43 vs 0.42 ± 0.13, p < 0.01) and Kurtzke Expanded Disability
Status Scale (4.64 ± 0.93 vs 2.56 ± 0.81, p < 0.01) than anti-AQP4 (-) ABS patients. Area postrema clinical brainstem
symptoms occurred more frequently in anti-AQP4 (+) ABS patients than those in anti-AQP4 (-) ABS patients (71.43 %
vs 17.65 %, p = 0.004). In examination of magnetic resonance imaging (MRI), the 78.57 % of anti-AQP4 (+) ABS patients
had medulla-predominant involvements in the sagittal view and dorsal-predominant involvements in the axial view.
Conclusions: ABS represents an inaugural or limited form of NMO in a high proportion of anti-AQP4 (+) patients.
Keywords: Acute brainstem syndrome, Anti-aquaporin 4 antibody, Neuromyelitis optica, Magnetic resonance imaging
Background
Acute brainstem syndrome (ABS) is an acute inflammatory
demyelinating syndrome of the CNS that may occur in iso-
lation or herald multiple sclerosis (MS), neuromyelitis
optica (NMO), or recurrences of brainstem syndrome
without other CNS manifestation (idiopathic recurrent
brainstem encephalitis [RBE]) [1]. Typical NMO is defined
by attacks of myelitis and optic neuritis (ON) [2]. The
aquaporin 4 (AQP4)-specific serum autoantibody, NMO-
IgG, is recognized as a specific biomarker for NMO [3]. In
NMO patients, ABS is untypical and not easily detected by
physicians [4–7] and brainstem symptoms commonly pre-
sented as nausea, vomit, intractable hiccup [8–15], so ABS
is easily neglected in NMO patients. In some cases of
NMO, ABS acts as the first manifestation, which should be
considered as a part of disease in addition to ON and
myelitis [4, 12, 13, 16].
ABS is recognized more frequently in patients with
NMO spectrum disorder (NMOSD), most brainstem
symptoms exist even before the diagnosis of NMOSD
[10–12, 17]. In diagnostic criteria of NMOSD in 2015,
ABS is considered as one of the core clinical characteris-
tics in the diagnosis of NMOSD [1]. In this study, the
predictive value of anti-AQP4 antibody for relapse or later
development was tested after the first sign of ABS.
Methods
Study population
Thirty-one patients with first-event ABS admitted to the
Third Affiliated Hospital of Sun Yat-sen University in
Guangzhou, China from January 2009 to September 2011
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were retrospectively analyzed. All the patients involved in
this study fulfilled the following inclusive criteria: 1) test
for NMO-IgG; 2) single clinical episode of ABS associated
with relevant brainstem MRI lesions 3) no other neuro-
logic signs or symptoms which suggested the diagnosis of
MS or NMO before NMO-IgG testing. Exclusion criteria
included previous or concomitant systemic autoimmune
diseases, metabolic etiology, vascular disorders and infec-
tions. All the patients were negative for HIV antibody.
The subjects provided written informed consent. This
study was conducted according to the principles expressed
in the Declaration of Helsinki and approved by the institu-
tion’s ethics committee. Lumbar puncture was also per-
formed with informed consent.
Data collection
Clinical features and outcomes including gender, age at
onset, duration, relapse times, annualized recurrence rate,
clinical manifestations, and magnetic resonance imaging
(MRI) findings were recorded in details. Analysis of
cerebrospinal fluid (CSF), serum anti-AQP4 test and
examinations of magnetic resonance imaging (MRI)
were performed within 2 weeks after attack of brain-
stem symptoms and before treatment. The diagnosis of
NMO, NMOSD and MS was based on Wingerchuk’s
criteria in 2006 [18], International consensus diagnostic
criteria for NMOSD in 2015 [1] and McDonald’s criteria
in 2010 [19] respectively. These symptoms, such as area
postrema clinical syndrome (including intractable hiccups,
nausea and vomiting), diplopia, and bulbar dysfunctions,
were regarded as the manifestation of brainstem symp-
toms. A relapse of ABS was defined as definite brainstem
symptoms of neurological dysfunction that lasted more
than 24 h, together with relevant brainstem lesions after
ruling out infective agents. Symptoms occurring within
1 month after the initial symptoms of relapse were con-
sidered to be part of the same episode. The neuro-
logical disability of the patients was assessed using the
Kurtzke Expanded Disability Status Scale (EDSS) [20].
A corticosteroid (1000 mg methyl prednisone, administered
intravenously for five consecutive days) was prescribed in
the acute stage and some patients received azathioprine in
the remission stage when developed as NMO.
AQP4 and oligoclonal bands testing
AQP4 antibodies were determined using a cell-based
assay on an AQP4-transfected cell line from a commercial
BIOCHIP kit (EUROIMMUN AG, Lübeck, Germany)
according to the manufacturer’s instructions. The CSF
oligoclonal bands (OCB) detection method used in our
laboratory was an isoelectric focusing technique combined
with the avidin-biotinperoxidase complex method.
MRI scanning
Brain and spinal cord MRI scans were carried out for all
patients using a GE 1.5 T MR scanner (General Electric,
Milwaukee, WI, USA). The slice thickness of the axial
scans was between 3 and 5 mm. Conventional MRI proto-
cols were used: T1 with and without gadolinium enhance-
ment (400/15.5 ms, TR/TE) and T2 (2500–3500/100 ms,
TR/TE) in spinal cord MRI; and T1 with and without gado-
linium enhancement (2128–2300/11.6–12.4 ms, TR/TE),
T2 (4600–4640/97.8–102 ms, TR/TE), and fluid-attenuated
inversion recovery (FLAIR) (8800/120 ms, TR/TE) in brain
MRI. A cross-sectional evaluation was also performed
on all MRI scans of the brain, and brainstem lesions
were classified as either having a ventral pattern, a
dorsal pattern. The spinal cord was segmented into cer-
vical and thoracolumbar regions. LETM is a spinal cord
lesion that extends over 3 or more vertebral segments.
All MRI scans were carried out prior to use of cortico-
steroid, immunomodulatory or immunosuppressive treat-
ment. An experienced neuroradiologist and a neurologist,
both of whom were blinded to the diagnostic cate-
gorization and the patients’ clinical features, each analyzed
all of the MRI scans. The final assessments were made by
consensus.
Statistical analysis
All statistical analyses were performed using Statistical
Program for Social Sciences (SPSS) statistical software
(version 16.0; Chicago, IL, USA). For each set of values,
data were expressed as the means ± standard deviation
(SD). Categorical variables were compared using Fisher’s
exact test. Non-categorical variables were compared
using the Mann-Whitney U test. Survival was estimated
according to the Kaplan-Meier method. The primary
study endpoint was the time to NMO conversion, as in-
dicated by the Wingerchuk’s criteria [18]. The log-rank
test was used to compare the survival analysis between
anti-AQP4 (+) and anti-AQP4 (-) ABS patients. All p-
values were two-tailed, with values of < 0.05 considered
significant. This study was an exploratory study so that
no adjustment for multiple comparisons was made.
Results
The data of 352 patients in our database were reviewed
between 2009 and 2011. A total of 31 patients who were
enrolled in this study satisfied the diagnostic criteria: 14
anti-AQP4 (+) patients with ABS and 17 anti-AQP4 (-)
patients with ABS. The details of the enrollment process
can be seen in the flowchart (Fig. 1).
Clinical characteristics
In 31 ABS patients (female-male ratio is 5.2:1) 14
(45.16 %) were positive for anti-AQP4 antibodies (Table 1).
The mean age of onset for anti-AQP4 (+) ABS patients
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(31.21 ± 8.81 years) was similar to that of anti-AQP4 (-)
patients (30.82 ± 8.55 years). According to Wingerchuk
criteria in 2006, 71.43 % anti-AQP4 (+) patients (10/14)
converted to NMO while only 11.76 % anti-AQP4 (-)
ABS patients (2/17) converted to NMO within the follow-
up after first-event brainstem symptoms (p < 0.01). The
100 % anti-AQP4 (+) patients (14/14) converted to
NMOSD while only 17.65 % anti-AQP4 (-) ABS pa-
tients (3/17) converted to NMOSD (p < 0.001) according
to International consensus diagnostic criteria for NMOSD
in 2015. The cumulative NMO conversion probability was
significantly higher in anti-AQP4 (+) patients than in anti-
AQP4 (-) patients (Table 1, OR 18.75; 95 % CI 2.871 to
122.452; p = 0.001).
Fig. 1 Study flowchart
Table 1 Comparison of clinical features between anti-AQP4 (+) and anti-AQP4 (-) patients with ABS
Clinical features Anti-AQP4 (+)
n = 14
Anti-AQP4 (-)
n = 17
Total
n = 31
P value
Female/male ratio 1:13 4:13 5:26 0.344
Age of onset (±SD) (years) 31.21 ± 8.81 30.82 ± 8.55 31.00 ± 8.52 0.902
Duration of follow-up (months) 46.35 ± 13.80 40.00 ± 11.30 44.51 ± 14.86 0.169
Number of episodes 3.71 ± 0.73 2.41 ± 1.54 3.00 ± 1.39 0.005
Annual relapse rate 1.05 ± 0.40 0.72 ± 0.40 0.87 ± 0.43 0.031
NMOSD 14/14 (100 %) 3/17 (17.65 %) 17/31 (54.84 %) <0.001
NMO 10/14 (71.43 %) 2/17 (11.76 %) 12/31 (38.71 %) 0.001
MS 0/14 (0.00 %) 7/17 (41.17 %) 7/31 (22.58 %) 0.007
Monophasic 0/14 (0.00 %) 7/17 (41.17 %) 7/31 (22.58 %) 0.007
CSF examinations
Total protein (mg/dl, ±SD) 0.30 ± 0.10 0.25 ± 0.12 0.27 ± 0.11 0.204
Cell counts (number/μl, ±SD) 11.29 ± 4.27 8.47 ± 2.07 9.74 ± 2.21 0.07
Pleocytosis >50WBC/μl (%) 2/14 0/17 2/31 0.196
IgG index 0.68 ± 0.07 0.42 ± 0.13 0.54 ± 0.17 <0.01
Oligoclonal bands 1/14 (7.14 %) 1/17 (5.88 %) 2/31 (6.45 %) 0.708
EDSS a 3 (2–4) 3 (2–3) 3 (2–4) 0.141
EDSS b 5 (3–7) 2.5 (1.5–4.5) 3.5 (1.5–7) <0.001
ABS acute brainstem syndrome, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disorder, MS multiple Sclerosis, ON optic neuritis,
CSF cerebrospinal fluid, EDSS Kurtzke Expanded Disability Status Scale, a, EDSS scores at the first attack; b, EDSS scores of the last visit of follow-up
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Brainstem symptoms
The brainstem symptoms of 31 ABS patients were
listed in Table 2. Five anti-AQP4 (+) patients (35.71 %)
experienced recurrent brainstem symptoms before the
attacks of ON or myelitis, while only one anti-AQP4 (-)
patients (5.88 %, p = 0.05) had more than one brainstem
attacks. Area postrema clinical brainstem symptoms,
such as hiccup (29.41 % vs 5.88 %, p = 0.05), nausea and
vomiting (64.28 % vs 17.65 %, p = 0.011), occurred more
frequently in anti-AQP4 (+) patients than those in anti-
AQP4 (-) patients.
MRI examinations
Brain and spinal cord MRI examinations were conducted
for all patients. On the sagittal section of brain MRI, the
lesions were more frequently occurred in the medulla of
anti-AQP4 (+) patients than those in anti-AQP4 (-) pa-
tients (78.75 % vs 35.29 %, p = 0.019). However, there were
no statistical differences in the other parts of brainstem
between these two groups, such as midbrain and pons
(Fig. 2, Table 3). Dorsal-predominant lesions were in-
volved more frequently in anti-AQP4 (+) patients than in
the anti-AQP4 (-) patients (58.33 % vs 22.22 %, p = 0.01).
The lesions in periependymal region were found more
common in anti-AQP4 (+) patients than in anti-AQP4 (-)
patients (35.29 % vs 7.14 %, p = 0.049) (Fig. 3, Table 3).
And the lesions in area postrema were found in 4 anti-
AQP4 (+) patients and 3 anti-AQP4 (-) patients (28.57 %
vs 17.64 %, p = 0.383) (Fig. 2, Table 3). None of the spinal
cord lesions were detected in the two groups when the ini-
tial episode of ABS. However, during the follow-up, seg-
ments of spinal cord lesions were longer in anti-AQP4 (+)
patients than in anti-AQP4 (-) patients (5 vs 2, p = 0.001)
(Table 4). LETM were also found more commonly in
anti-AQP4 (+) patients (64.29 % vs 17.65 %, p = 0.012)
at the duration of follow-up (Table 4).
CSF examinations
CSF specimens were obtained from all patients at the
acute stage (Table 1). The protein concentrations in CSF
of anti-AQP4 (+) patients (0.30 ± 0.10 mg/dl) were similar
with those of anti-AQP4 (-) patients (0.25 ± 0.12 mg/dl).
Anti-AQP4 (+) patients had a slightly higher number of
white blood cells (WBCs) in CSF (11.29 ± 4.27) than anti-
AQP4 (-) patients (8.47 ± 2.07). However, the values of
IgG index in anti-AQP4 (+) patients were significantly
higher than those of anti-AQP4 (-) patients (0.68 ± 0.07 vs
0.42 ± 0.13, p < 0.01). Only one anti-AQP4 (+) ABS pa-
tient and one anti-AQP4 (-) ABS patient were positive
for OCBs in CSF.
Prognosis in ABS patients
All the patients were followed up at least 2 years after
the first episode of ABS. The median duration of follow-
up was 42 months (24–65 months). 7/31 (22.58 %) of
patients did not show a second episode during the
follow-up period, 12/31(38.70 %) of patients developed
to NMO, 17/31(54.84 %) of patients converted to
NMOSD, and 7/31(22.58 %) of patients converted to
MS. In the follow-up duration, the mean annual relapse
rates of anti-AQP4 (+) patients were significantly higher
than those of anti-AQP4 (-) patients (1.05 ± 0.40 vs
0.72 ± 0.40, p = 0.031) (Table 1). Although the EDSS
scores at the first attack were similar between two
groups, anti-AQP4 (+) patients presented a significantly
higher EDSS scores than anti-AQP4 (-) patients at the
last visit of follow-up [5(3–7) VS 2.5(1.5–4.5), p < 0.01].
Kaplan-Meier survival analysis showed that the risk of
developing to NMO in anti-AQP4 (+) patients were
Table 2 Comparison of brainstem symptoms between anti-AQP4 (+) and anti-AQP4 (-) patients with ABS
Onset symptoms Anti-AQP4 (+) Anti-AQP4 (-) Total P value
n = 14 n = 17 n = 31
Diplopia 6/14 (42.86 %) 8/17 (47.06 %) 14/31 (45.16 %) 0.551
Area postrema clinical syndrome 10/14 (71.43 %) 3/17 (17.65 %) 13/31 (41.94 %) 0.004
Intractable hiccup 5/14 (29.41 %) 1/17 (5.88 %) 6/31 (19.35 %) 0.05
Nausea and vomiting 9/14 (64.28 %) 3/17 (17.65 %) 12/31 (38.71 %) 0.011
Bulbar dysfunction 5/14 (35.71 %) 6/17 (35.29 %) 11/31 (35.48 %) 0.636
Dysarthria 1/14 (7.14 %) 3/17 (17.65 %) 4/31 (12.90 %) 0.378
Dysphagia 2/14 (14.29 %) 4/17 (23.53 %) 6/31 (19.35 %) 0.429
Alalia 2/14 (14.29 %) 0/17 (0 %) 2/31 (6.45 %) 0.196
Vertigo 4/14 (28.57 %) 7/17 (41.18 %) 11/31 (35.48 %) 0.364
Facial paralysis 2/14 (14.29 %) 5/17 (29.41 %) 7/31 (22.58 %) 0.287
Ataxia 3/14 (21.43 %) 7/17 (41.18 %) 7/31 (22.58 %) 0.218
Quadriplegia 2/14 (14.29 %) 1/17 (5.88 %) 3/31 (9.68 %) 0.425
ABS acute brainstem syndrome
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significantly higher than that in anti-AQP4 (-) patients
(log rank 5.23, p = 0.012) (Fig. 4).
Discussion
NMO frequently begins with an acute or subacute epi-
sode of ON or myelitis. However, brainstem symptoms
in NMO were not rare [8, 10–12, 17]. According to the
previous studies, brainstem symptoms have recently
been described in NMO as well as in NMOSD [10, 12,
13, 17, 21]. In 17.05–30.61 % NMO patients, brainstem
symptoms even act as the sole manifestation [14, 17].
“Brainstem symptoms with anti-AQP4 antibodies” has
also been recommended in the latest diagnostic criteria
for NMOSD [1]. Various brainstem symptoms such as
area postrema clinical brainstem symptoms (including
intractable hiccups, nausea and vomiting), diplopia, and
bulbar dysfunctions attributed to lesions in the dorsal re-
gion of the medullar and the pons surrounding the
fourth ventricle could be the first manifestation of symp-
toms [9, 10, 12, 14]. Our results demonstrated that area
Fig. 2 Axial T2-weighted (a and b; arrow) and sagittal T2 FLAIR (c; arrow) MRI show lesions occur in the medulla oblongata. Axial T2 FLAIR (d and
e; arrow) MRI show pericanal lesions occur in the medulla oblongata. Linear faint Sagittal-T2-weighted high intensity signals are shown in the
medulla oblongata (f; arrow)
Table 3 Comparison of brainstem MRI between anti-AQP4 (+) and anti-AQP4 (-) patients when the initial episode of ABS
MRIs Anti-AQP4 (+) Anti-AQP4 (-) Total P value
n = 14 n = 17 n = 31
Brainstem lesions
Sagittal view
Pons 6/14 (42.86 %) 8/17 (47.06 %) 14/31 (45.16 %) 0.551
Midbrain 3/14 (21.43 %) 5/17 (29.41 %) 8/31 (25.81 %) 0.466
Medulla 11/14 (78.57 %) 6/17 (35.29 %) 17/31 (54.84 %) 0.019
Axial view
Dorsal 11/14 (78.57 %) 7/17 (41.17 %) 18/31 (58.06 %) 0.04
Ventral 3/14 (21.43 %) 10/17 (58.82 %) 13/31 (41.94 %) 0.04
Periependymal region 3/14 (21.43 %) 1/17 (5.88 %) 4/31 (12.90 %) 0.228
Area postrema 4/14 (28.57 %) 3/17 (17.64 %) 7/31 (22.58 %) 0.383
ABS acute brainstem syndrome
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postrema clinical brainstem symptoms in anti-AQP4 (+)
ABS patients were more frequent than those in anti-
AQP4 (-) ABS patients. Intractable hiccups, nausea, and
vomiting have been reported as unique symptoms in
NMO due to the involvement of the pericanal region in
the medulla oblongata, which included the areas post-
rema, nucleus tractus solitaries where the putative
hiccup and vomiting centres are located [13, 14]. In our
study, intractable hiccups, nausea, and vomiting occur in
71.43 % anti-AQP4 (+) ABS patients, which are more
frequent than in anti-AQP4(-) ABS patients. Previous
study also confirmed that intractable hiccups, nausea,
and vomiting are clinical markers for the early phase of
an exacerbation in NMO [22]. In addition, anti-AQP4
(+) ABS patients are prone to have recurrent brainstem
symptoms before attacks of ON or myelitis.
In addition to clinical features, the distribution of
brainstem lesions of anti-AQP4 (+) ABS patients also is
different from anti-AQP4 (-) ABS patients. Although the
midbrain and pons in the sagittal view are involved both
in anti-AQP4 (+) ABS patients and anti-AQP4 (-) ABS
patients, the medulla segments are more frequently in-
volved in anti-AQP4 (+) ABS patients. In the axial view,
anti-AQP4 (+) ABS patients present dorsal-predominant
involvement, which is consistent with our previous re-
port [23]. In AQP4 (+) ABS patients, majority of the
Fig. 3 Axial T2-weighted FLAIR MRI shows periependymal lesions are involved in the dorsal midbrain (a, b and f, g; arrow) and pons (c, d and h, i; arrows).
Sagittal T2-weighted FLAIR MRI shows increased signal surrounds the fourth ventricle (e and j; arrows)
Table 4 Comparison of brain and spinalcord MRI between anti-AQP4 (+) and anti-AQP4 (-) patients during follow-up
MRIs Anti-AQP4 (+) Anti-AQP4 (-) Total P value
n = 14 n = 17 n = 31
Brain MRIs
Lesions in other brain regions
Juxtacortical 0/14 (0) 2/17 (11.76 %) 2/31 (6.45 %) 0.488
Subcortical 1/14 (7.14 %) 5/17 (29.41 %) 6/31 (19.35 %) 0.185
Infratentorial 14/14 (100 %) 17/17 (100 %) 31/31 (100 %)
Spinal cord MRI
Segments 5 (3–7) 2 (0–4) 3.5 (0–8) 0.001
Cervical 10/14 (71.43 %) 13/17 (76.47 %) 23/31 (74.19 %) 0.750
Thoracic 7/14 (50 %) 5/17 (29.41 %) 12/31 (38.71 %) 0.242
Cervical and thoracic 3/14 (21.43 %) 1/17 (5.88 %) 4/31 (12.90 %) 0.199
LETM 9/14 (64.29 %) 3/17 (17.65 %) 12/31 (38.71 %) 0.012
Meet Barkhof criteria 0/14 (0 %) 5/17 (29.41 %) 5/31 (16.13 %) 0.185
Cheng et al. BMC Neurology  (2016) 16:203 Page 6 of 9
lesions (78.57 %) are observed in the medulla including
28.57 % lesions occurring in the area postrema. There is
an agreement between MRI findings and clinical presen-
tation of brainstem lesions. This study supports that the
brainstem, especially medulla and area postrema, is the
important region of attack in NMO [11, 17].
NMO-IgG has been proved to be highly specific and
moderately sensitive to NMO. The prevalence of anti-
AQP4 antibodies in NMO patients ranged from 50–
60 % [3, 24–26]. However, NMO-IgG is not restricted to
these patients fulfilling all criteria for a definite diagnosis
of NMO [27–29]. This antibody is also identified in
partial syndromes, the frequency of anti-AQP4 in acute
partial transverse myelitis is 4.5 % [30], while 26.9 % in
recurrent ATM [31], increasing to 37.9–60 % in LETM
[27, 31, 32] and 20 % in recurrent ON [33], 5.8 % in
acute monosymptomatic ON [34]. Our study provided
that the frequency of anti-AQP4 in ABS is 45.16 %.
Currently, sensitive marker(s) to predict the conversion
of ABS to NMO are still absent. Our results found that
100 % of the anti-AQP4 (+) ABS patients experience
clinical relapse, and 71.43 % of anti-AQP4 (+) ABS pa-
tients convert to NMO in the following 3 years, while
only 11.76 % of the anti-AQP4 (-) ABS patients convert
to NMO, and the cumulative NMO conversion probability
is significantly higher in anti-AQP4 (+) ABS patients than
that in anti-AQP4 (-) ABS patients. These results are
similar to those patients with ON or LETM as the initial
presentation, which also demonstrated a rapid NMO con-
version in the first 2 years after the initial episode [32, 35].
The results suggested that anti-AQP4 antibodies may be
useful for diagnosis and prognosis of patients who pre-
sented with isolated ABS. Moreover, 29.42 % of anti-
AQP4 (+) ABS patients experience recurrent brainstem
symptoms before attack of ON or myelitis, which
suggested that anti-AQP4 antibody associated recurrent
brainstem symptoms should be paid more attention. The
anti-AQP4 (+) ABS patients are at high risk for develop-
ment of severe disability.
Several studies have also identified a new antigenic
target, myelin oligodendrocytic glycoprotein (MOG), as
being of interest in seronegative AQP4 patients [36].
Compared with AQP4-positivity patients, serum MOG
antibodies do have a distinct clinical phenotype from
AQP4-positivity NMO that is characterized by fewer re-
lapses, a better clinical outcome, and a wider spectrum
of MRI features, which may suggest a sort of disease dis-
tinct from NMO or MS [37–39]. This antibody is found
in around 20 % of AQP4-seronegative patients. MOG
testing was not performed in this study, therefore we
can’t exclude the bias of MOG-seropositive patients in
our AQP4 negative cohort. However, brainstem lesions,
which are a hallmark of AQP4-seropositive NMO/
NMOSD, occur less frequently in MOG-seropositive pa-
tients [38, 40]. Moreover, the primary endpoint of our
study is the conversion of typical NMO. Therefore, this
would make little impact on our results.
Therapy of NMO should be initiated early. Azathio-
prine and rituximab are suggested as first-line treat-
ments [41]. In patients with NMOSD, IFN-β treatment
[42], glatiramer acetate [43], natalizumab [44] and fingo-
limod (FTY720) [45] are ineffective for preventing re-
lapses or fail to control disease activity. In our study, no
patients received the above treatments, which might
have treatment effects on accumulative NMO conver-
sion probability. Therefore, the risk of conversion to
NMO in anti-AQP4 (+) ABS patients seems higher in
the first 2 years based on this study. We recommend
that all patients with ABS make test for NMO-IgG and
that seropositive patients receive immunosuppressive
treatments which are effective in reducing NMO relapse
frequency, such as azathioprine or rituximab.
Conclusions
ABS represents an inaugural or limited form of NMO in
a high proportion of anti-AQP4 (+) patients.
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